diethylcarbamazine

(redirected from diethylcarbamazine citrate)
Also found in: Medical.

diethylcarbamazine

[‚dī‚eth·əl‚kär′bam·ə‚zēn]
(organic chemistry)
C16H29O8N3 White, water-soluble, hygroscopic crystals, melting at 136°C; used as an anthelminthic.
Mentioned in ?
References in periodicals archive ?
Becoming a signatory to the London Declaration, Eisai agreed to support the World Health Organization's program to eliminate lymphatic filariasis, and has committed to supplying diethylcarbamazine citrate (DEC) until the disease is eliminated in all lymphatic filariasis endemic countries that need DEC.
Fortunately, there is a simple cure for these conditions: salt fortified with iodine and diethylcarbamazine citrate (DEC).
Nadda launched the Accelerated Plan for Elimination of Lymphatic Filariasis (APELF) for India and announced the phased roll-out of the Triple Drug Therapy or IDA (Ivermectin, diethylcarbamazine citrate and albendazole) in India.
The recommended approach is annualized supervised MDA through door to door visit by coadministration of a single doses of diethylcarbamazine citrate (DEC) by 2 days mopping up operations.
Since 1947, diethylcarbamazine citrate (DEC) has been used in the treatment and control of lymphatic filariasis, which is caused by the nematodes Wuchereria bancrofti, Brugia malayi, and B.
In order to eliminate transmission and to prevent disability due to LF by the year 2015, sixteen districts of Andhra Pradesh have been under mass drug administration (MDA) programme, covering 54 million population with annual single dose of diethylcarbamazine citrate (DEC) tablets orally (1).
Background & objectives: Albendazole, a commonly used anthelminthic drug that targets the polymerization of [alpha]- and [beta]-tubulin dimer is currently co-administered with the antifilarial drug, diethylcarbamazine citrate (DEC) in the ongoing Global Programme for Elimination of Lymphatic Filariasis (GPELF).
In the ATM Index 2014 report, Eisai's commitment to eliminating lymphatic filariasis, a neglected tropical disease, by providing 2.2 billion diethylcarbamazine citrate (DEC) tablets to endemic countries in collaboration with the World Health Organization (WHO) for seven years period starting from 2013, was also highly commended.